Lv4
720 积分 2025-03-22 加入
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
1个月前
已完结
Medical treatment for active breast cancer brain metastases
1个月前
已完结
多发性骨髓瘤双特异性抗体治疗相关感染管理中国专家共识（2026年版）
1个月前
已完结
大颗粒淋巴细胞白血病诊断与治疗中国专家共识（2026年版）
1个月前
已完结
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
1个月前
已完结
Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma
1个月前
已完结
Treatment Decisions in Multiple Myeloma
1个月前
已完结
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
1个月前
已完结
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
1个月前
已完结
皖公网安备34019202002308
